Drug Profile
Research programme: CFTR correctors - Parion Sciences
Latest Information Update: 26 Apr 2023
Price :
$50
*
At a glance
- Originator Parion Sciences
- Class Small molecules
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 26 Apr 2023 Discontinued - Preclinical for Cystic fibrosis in USA (PO)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Cystic-fibrosis in USA (PO)
- 16 Sep 2014 Preclinical trials in Cystic fibrosis in USA (PO)